Introduction
Oncogenic activation of the RET kinase is a common event in papillary thyroid carcinomas (PTC) (reviewed in Vecchio and Santoro, 2000; Santoro et al., 2002) , especially in patients with history of radiation exposure (Bounacer et al., 1997; Nikiforov et al., 1997; Santoro et al., 2000) . Activation of the RET oncogene in PTC is the result of recombination events leading to the fusion of the RET tyrosine kinase with 5 0 -fragments of heterologous genes, the most common of which are the H4 gene, the gene encoding the RIa regulatory subunit of the cAMP-dependent protein kinase, and the RFG gene (reviewed in Puxeddu and Fagin, 2001 ). These rearrangements have been termed RET/PTC1, RET/ PTC2, and RET/PTC3, respectively. RET is not normally expressed in thyroid follicular cells; however, fusion with the 5 0 -fragment of the heterologous gene provides an active promoter driving expression of the chimeric gene. The partner gene in the rearrangement also provides the N-terminal portion of the resulting fusion protein, which contains a dimerization domain that results in constitutive activation of the RET tyrosine kinase. A number of downstream signal pathways activated by RET and RET/PTC have been identified. RET kinase activation results in autophosphorylation of tyrosine residues Y905, Y1015, Y1062, and Y1096 of the full-length RET Salvatore et al., 2000) and generation of docking sites for adaptor proteins. Thus, Y905 of full-length RET is a docking site for the adaptor proteins Grb7 and Grb10 (Pandey et al., 1995 Durick et al., 1996) , Y1015 for PLCg, (Borrello et al., 1996; Durick et al., 1996) , Y1062 for Shc, enigma, and FRS2 (Arighi et al., 1997; Besset et al., 2000; Hayashi et al., 2000; Melillo et al., 2001) , and Y1096 for Grb2 (Alberti et al., 1998; Besset et al., 2000) .
Thyroid follicular cells are characterized by the expression of a variety of proteins that are unique to this cell type. The combined function of these genes results in TSH-regulated synthesis of thyroid hormone. Thyroid-specific expression of thyroglobulin (Tg), thyroid peroxidase (TPO), sodium iodide symporter (NIS), and the TSH receptor is regulated by at least three transcription factors TTF1, TTF-2, and the paired box factor Pax-8 . The promoters of the Tg and TPO genes contain binding sites for Pax-8 and TTF-1 (Civitareale et al., 1989; Sinclair et al., 1990; Zannini et al., 1992) . Moreover, both of these transcription factor activate the Tg and TPO promoters in heterologous cell systems (Francis-Lang et al., 1992a; Zannini et al., 1992) . In contrast to Tg and TPO, expression of NIS requires factors in addition to Pax-8 and TTF-1 (Ohno et al., 1999; Chun and Di Lauro, 2001; Schmitt et al., 2002) .
RET/PTC rearrangements are an initiating event in the development of thyroid papillary carcinomas. This hypothesis is supported by the following observations: (1) Expression of RET/PTC1 or 3 in the thyroid of transgenic mice results in tumors resembling papillary carcinomas (Jhiang et al., 1996; Santoro et al., 1996; Powell et al., 1998) ; (2) The rearrangement is found in occult thyroid papillary microcarcinomas, which represent early stages of papillary tumors (Viglietto et al., 1995; Sugg et al., 1998) ; (3) Irradiation directly induces RET/PTC rearrangements in undifferentiated thyroid carcinomas and fibrosarcoma cell lines (Ito et al., 1993) as well as human fetal thyroid explants (Mizuno et al., 1997 (Mizuno et al., , 2000 .
Expression of RET/PTC1 or RET/PTC3 in thyroid glands of transgenic mice causes hypothyroidism (Jhiang et al., 1998; Powell et al., 1998) . This is likely because of decreased expression of thyroid-specific genes, as expression of RET/PTC1 in PCCL3 cells inhibits Tg, TPO, and NIS mRNA abundance (Santoro et al., 1993; De Vita et al., 1998; Trapasso et al., 1999) . The RET/PTC1-induced decrease in thyroid-specific gene expression in PCCL3 cells is associated with decreased Pax-8 expression as well as impairment in the activity of the transcription factors TTF-1 and Pax-8 (De Vita et al., 1998) . However, signal transduction pathways downstream of RET/PTC that are involved in its dedifferentiating effects have not been investigated. To study this we generated clonal cell lines derived from the well-differentiated rat thyroid cell line PCCL3, with doxycycline-inducible expression of RET/PTC mutants that are unable to interact with either PLCg or Shc, two downstream signaling intermediates important in mediating transformation of fibroblasts by RET/PTC (Borrello et al., 1996 , Durick et al., 1998 , Mercalli et al., 2001 .
Results and Discussion
Stable expression of RET/PTC1 in rat thyroid PCCL3 cells has previously been shown to be associated with a decrease in thyroid-specific gene expression (De Vita et al., 1998; Trapasso et al., 1999) . Using PCCL3 cells with doxycycline inducible expression of RET/PTC3, we observed that expression of this variant of the oncoprotein induces a time-dependent decrease in TSH-dependent Tg and NIS mRNA, which is associated with lower Pax-8 mRNA levels (Figure 1) . Thus, like RET/PTC1 and RET/PTC2, RET/PTC3 promotes dedifferentiation of thyroid cells. Given the high degree of structural similarity between the different RET/PTC oncoproteins, it is likely that similar mechanisms are involved in the dedifferentiating effects of these oncoprotein variants. In a previous report, the RET/PTC1-induced decrease in Tg and NIS expression was demonstrated to be associated with a decrease in Pax-8 mRNA. In addition, RET/PTC1 also inhibited its transcriptional activity, as overexpression of Pax-8 was not able to reverse the decrease in Tg and NIS mRNA expression (De Vita et al., 1998) . Regulation of Pax-8 activity is not completely understood, but likely involves cAMPdependent transactivation of the Pax-8 promoter (Medina et al., 2000; Mascia et al., 2002) and possible TSH-dependent synthesis of one or more additional proteins (Mascia et al., 2002) . The RET/PTC-induced decrease in thyroid-specific gene expression is also likely to involve inhibition of a second transcription factor, TTF-1, as RET/PTC1 and RET/PTC2 expression have previously been shown to inhibits its activity (De Vita et al., 1998) . The effects of RET/PTC on TTF-1 are likely to be restricted to post-translational effects, as its protein levels are not changed by expression of RET/ PTC.
The major goal of this study was to map the signal transduction pathways downstream of RET/PTC responsible for RET/PTC-induced thyroid cell dedifferentiation. For this, we generated clonal lines derived from PCCL3 cells with doxycycline-inducible expression of the following RET/PTC mutants: RET/PTC3 Y541F , in which Y541 (corresponding to Y1015 of full-length Ret) was changed to phenylalanine; and PTC2/PDZ, in which the 22 most C-terminal amino acids, including Y1062, were removed and replaced with the PDZ domain of Enigma to insure proper membrane targeting of the truncated receptor. We elected to use this strategy to explore the role of Y1062, since this same tyrosine is also necessary for membrane localization of RET/PTC2 through interaction with Enigma. Thus, simple substitution of Y1062 is likely to result in more profound disruption of function, through mislocalization away from the plasma membrane (Durick et al., 1998) . Western blots of lysates from cells treated for 24 h with doxycycline demonstrated that wild-type RET/PTC3 and the different RET/PTC mutants were expressed at similar levels ( Figure 2a) . Substitution of the tyrosine corresponding to amino acid 1062 of full-length RET has been shown to prevent the association of RET and RET/PTC with Shc. Coupling to Shc has previously been demonstrated to be required for RET/PTCinduced activation of Ras and its downstream signaling partners (van Weering et al., 1995; Durick et al., 1998) . To confirm that removal of the 22 C-terminal amino acids prevents the association of RET/PTC with Shc in PCCL3 cells, a rabbit anti-Shc IgG was used to immunoprecipitate Shc from the indicated cell extracts and the resulting immunoprecipitates subjected to Western blotting with anti-RET. (Figure 3 ). By contrast, the expression of these two gene products was not affected by expression of PTC2/PDZ (Figure 3) , suggesting that Y541 (equivalent to Y1062 of full-length RET) is required for the dedifferentiating effects of RET/PTC. This tyrosine residue has been demonstrated to interact with different adaptor proteins (Melillo et al., 2001) , and thus could potentially be involved in the activation of a number of independent signal transductions pathways. To explore which of these was responsible for the dedifferentiating effects of RET/ PTC, we initially examined the role of the Ras/Raf/ MEK/MAPK pathway, because it was previously shown to decrease NIS and Tg expression in PCCL3 cells (Fusco et al., 1987; Missero et al., 2000) . We first tested the effects of MEK inhibitors on RET/PTC3-induced downregulation of Tg and NIS expression. Addition of the MEK inhibitors PD98059 or U0126 blunted the inhibitory effects of RET/PTC on expres- While not previously demonstrated, a role for H-Ras in mediating the effects of RET/PTC is not surprising given its previously reported effects on thyroid-specific gene expression (Fusco et al., 1987; Francis-Lang et al., 1992b) . As with RET/PTC, the H-Ras
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-induced decrease in expression of these genes is associated with a reduction in TTF-1 transcriptional activity (FrancisLang et al., 1992b; Velasco et al., 1998) .
To determine whether activation of Ras or MEK1 was sufficient to recapitulate the effects of RET/PTC3 on NIS and Tg expression, we used previously characterized cell lines derived from PCCL3 cells with doxycycline-inducible expression of H-Ras V12 or MEK1 E217/E221 Shirokawa et al., 2000) . As observed with RET/PTC3, expression of either H-Ras V12 or MEK1 E217/E221 blocked TSH-induced expression of NIS and Tg ( Figure 5 ). Moreover, these effects of H-Ras V12 and MEK1 E217/E221 were also abrogated by MEK inhibitors.
Our observation that the constitutively active MEK1 mutant, MEK1 E217/E221 , inhibits Tg and NIS expression is in contrast to a previous report that found expression of the constitutively active MEK1 mutant, MEK DN3/S221E/ S222 , had no affect on thyroid-specific gene expression . A possible reason for the seemingly contradictory results is the lack of a nuclear localization signal in MEK DN3/S221E/S222 that is present in the MEK1 E217/E221 mutant. In a subsequent report by the same group (Missero et al., 2000) -+ -+
-TSH +TSH

NaI symporter
Dox (1 µg/ml) Figure 3 Effects of RET/PTC mutants on thyroid-specific gene expression. Cells were incubated for 3 days in H3 medium and then dox was added for 12 h. The medium was then replaced with fresh H3 or H4 medium with or without dox (1 mg/ml) and the cells were incubated for 48 h and RNA was isolated. Northern blots containing 10 mg of total RNA from the indicated cell lines were hybridized with Tg, NIS, or a cyclophilin cDNA probe
U0126 (10 µM)
Pax-8 Figure 4 Effects of MEK inhibitors on RET/PTC-induced decrease in thyroid-specific gene expression. Cells were incubated for 3 days in H3 medium and then dox (1 mg/ml) and the indicated MEK inhibitor were added for 12 h. The medium was then replaced with fresh H3 or H4 medium with or without dox and containing the indicated MEK inhibitor. Cells were then incubated for 48 h and RNA was isolated. Northern blots containing 10 mg of total RNA from PTC3-5 cells treated as indicated were hybridized with a Tg, NIS, or a Pax-8 cDNA probe. Ethidium bromide staining of the 28S ribosomal RNA was used as a loading control
Ras/MEK1 Figure 5 Effects of doxycycline-induced expression of H-Ras V12 or MEK1 E217/E221 on thyroid-specific gene expression. Cells were incubated for 3 days in H3 medium and then treated with dox (1 mg/ml) and the indicated concentration of PD98059 for 12 h. The medium was then replaced with H4 medium with or without dox and containing the indicated concentration of PD98059. Cells were then incubated for 48 h and RNA isolated. Northern blots containing 10 mg of total RNA from the indicated cell lines were hybridized with a Tg, Pax-8, MEK1, Ras, or a NIS cDNA probe. Ethidium bromide staining of the 28S ribosomal RNA was used as a loading control decrease in thyroid-specific gene expression was observed, the authors suggest that stable expression of MEK DN3/S221E/S222 results in inefficient activation of ERK in vivo compared to that elicited by the RAS oncogene, possibly because of the lack of a nuclear export signal likely explaining the lack of effect of this MEK1 mutant.
Our data indicate that a domain within the 22 amino acid C-terminal of the RET/PTC, in all likelihood corresponding to Y1062, is required for the dedifferentiating effects of RET/PTC in rat thyroid cells. We cannot completely rule out the possibility that other signal motifs within the 22 amino acid C-terminal are responsible for this effect. However, the lack of association of PTC2/PDZ with Shc and restoration of TSH-induced gene expression by MEK inhibitors support a role for Ras/Raf/MEK/MAPK pathway. Whether additional pathways activated by Ras or RET/PTC are also involved is uncertain. The observation that the Ras V12N38 mutant, which does not activate the Raf/MEK/MAPK pathway, cooperates with constitutively active C-Raf for complete inhibition of TTF-1 activity (Missero et al., 2000) suggests that pathways downstream of Ras in addition to Raf/MEK/MAPK may also be involved.
This and other studies (Francis-Lang et al., 1992b; Velasco et al., 1998; Missero et al., 2000) clearly demonstrate a dedifferentiating effect of RET/PTC or oncogenic Ras in clonal rat thyroid cell lines. However, a recent report (Gire and Wynford-Thomas, 2000) showing that retroviral-mediated transduction of HRas V12 in human primary culture does not inhibit Tg or TPO expression casts some doubt on the role of oncogenic RAS in thyroid cell dedifferentiation. Possible explanations for the conflicting effects of oncogenic RAS in these two experimental systems are species differences or, perhaps more likely, that additional alterations have occurred in the immortalized cell lines that enable the dedifferentiating effects of oncogenic RAS and RET/PTC to manifest. On the other hand, mutations of Ras and RET/PTC are prevalent in thyroid neoplasms in which differentiated gene expression is indeed compromised (Fabbro et al., 1994) . Moreover, mice with targeted expression of RET/ PTC1 or RET/PTC3 in thyrocytes become hypothyroid (Powell et al., 1998) . The evidence shown here that MEK inhibitors increase Tg and NIS mRNA levels in cells expressing RET/PTC, RAS V12 , or MEK1 E217/E221 suggests that inhibiting the RAF/MEK/MAPK pathway may promote redifferentiation in poorly differentiated thyroid tumors with constitutive activation of either Ras or RET/PTC.
Materials and methods
Cell culture
The well-differentiated rat thyroid cell line PCCL3 (Fusco et al., 1987) was propagated in H4 medium, which consisted of Coons modification of Ham's F12 media (Irvine Scientific, Irvine, CA, USA) containing 5% fetal calf serum, glutamine (286 mg/ml), apo-transferrin (5.0 mg/ml), hydrocortisone (1.0 nm), insulin (1.0 mg/ml), TSH (1.0 mIU/ml), penicillin, and streptomycin. H3 medium is identical to H4 medium except TSH has been omitted.
DNA constructs and site-directed mutagenesis DNA constructs The PT2C/PDZ cDNA in which nucleotides encoding for the 22 most C-terminal amino acids (including Y1062) were replaced with the Enigma PDZ domain was provided by Susan Taylor, University of California San Diego (Durick et al., 1998) . The RET/PTC3 cDNA was provided by Sissy Jhiang, Ohio State University.
Site-directed mutagenesis RET/PTC3
Y541F was created by changing Y541 (corresponding to Y1015 in full-length RET) to phenylalanine using a previously described method (Mikaelian and Sergeant, 1992) . Briefly, we first created fragment A with the pUGH10-3 vector-specific sense primer ret-F1 5 0 agctcgtttagtgaa 3 0 , the RET/PTC3 specific antisense primer ret-R2 5 0 tagtctcagggccgtcgtcataaa 3 0 , using the pUHG 10-3-RET/PTC3 construct as template. The underlined nucleotides of the ret-R2 primer correspond to the RET/PTC3 cDNA. Fragment B was then created by amplification of the same template with RET/PTC3-specific sense primer ret-F2 5 0 aggagagactTcttggacctt 3 0 and the vector-specific antisense primer ret-R1 5 'ttctaaacaacaccctg 3 '. The sense primer converted the codon corresponding to 1015 in full-length Ret from TAC to TTC. Fragments A and B were then denatured, annealed, and amplified using the primers ret-F1 and ret-R1. The resulting PCR product was then cut with XbaI and SacII, and ligated into the pUG10-3 vector. The correct cDNA sequence was then verified using an ABI sequencing machine.
Cell lines
The PCCL3-rtTA-7 cell line was created by stably transfecting PCCL3 cells , with pUHD172-1neo that directs high level expression of the reverse tetracycline transactivator protein (Gossen et al., 1995) . PCCL3 cell lines with doxycycline-induced expression of RET/PTC3, RET/PTC3 Y541F (Y541 corresponds to Y1015 in full-length RET), or PTC2/PDZ were created by subcloning the respective cDNA into the pUHG10-3 vector developed by coworkers (Gossen and Bujard, 1992, 1993) , downstream of the heptamerized tetO and a minimal CMV promoter. The constructs were then cotransfected with TKhygro, which contains the hygromycin gene under control of a minimal TK promoter, into the PCCL3-rTTA-7 cell line. As a control, the pUHG10-3 vector was transfected into the PCCL3-rTTA-7 cell line to generate rtTA-Cl3. The cell lines with doxycycline-inducible expression of the constitutively active H-Ras mutant, H-Ras
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, and the constitutively active MEK1 mutant, MEK1 E217/E221 , have been previously described Shirokawa et al., 2000) . In all cases at least one additional clone with inducible expression of the indicated cDNA was examined with similar results to those reported.
Lysate preparation, immunoprecipitation, and Western blotting Total cell lysates Cells were harvested and placed in ice-cold buffer A (10 mm Tris-HCl pH 7.5, 5 mm EDTA, 100 mg/ml PMSF, 4 mm EGTA, 1 mg/ml aprotinin, 5 mg/ml E-64, 1 mg/ml leupeptin, and 1 mg/ml pepstatin) containing 1% Triton X-100 and lysed by passage through a 27 gauge needle. The lysate was then centrifuged at 10 000 Â g for 15 min at 41C, the supernatant collected, and the protein concentration determined. An equal amount of protein from each sample was then subjected to SDS-PAGE.
Preparation of soluble and particulate fractions Cells were harvested and placed in ice-cold buffer A and lysed by passage through a 27 gauge needle. Soluble and particulate fractions of the cell lysates were then separated by centrifugation at 100 000 Â g for 1 h at 41C. The supernatant (soluble fraction) was removed and the pellet resuspended in buffer A containing 1% Triton X-100. The Triton X-100 insoluble material was removed by centrifugation at 100 000 Â g for 1 h at 41C and the supernatant collected (particulate fraction). The distribution of RET/PTC in the various fractions was then analysed by Western blotting.
Immunoprecipitation Cells were grown in H4 medium until confluent and then incubated in H3 medium for 2 days. The medium was then replaced with fresh H3 medium with or without dox (1 mg/ml) and incubated for 24 h. Cells were lysed with 1 ml of buffer B (50 mm Tris (pH7.5), 200 mm NaCl, 0.5% Nonidet P-40, and 0.5% deoxycholate). Cell lysates were then incubated with rabbit anti-PLCg or rabbit anti-Shc for 1 h at room temperature, followed by a 1h incubation with protein A/G plus agarose. The agarose beads were then washed three times with buffer B and collected by centrifugation. The immunoprecipitated proteins were then analysed by Western blotting.
Western blot analysis Protein samples or immunoprecipitated proteins were subjected to SDS-PAGE and transferred to nitrocellulose membranes. Membranes were hybridized with antibodies to the indicated proteins, and then with their corresponding species-specific horseradish peroxidase-conjugated secondary IgG and bands visualized using ECL (Amersham Pharmacia Biotech Inc, Piscataway, NJ, USA) as directed by the manufacturer. The images were captured using the Kodak Image Station or X-ray film (Kodak, Eastman Kodak Co., New Haven, CT, USA). Mouse monoclonal anti-Ret IgG was a gift from Dr Yuri Nikiforov (University of Cincinnati) and rabbit anti-Ret was a gift from Drs Massimo Santoro and Alfredo Fusco (University of Naples). The following IgGs were purchased from Santa Cruz (Santa Cruz, CA, USA): rabbit anti-PLCg, rabbit anti-Shc, mouse anti-Shc, mouse anti-insulin receptor, mouse antiphospho tyrosine, control rabbit IgG.
RNA preparation and Northern blotting
Cells were harvested at the indicated time and RNA isolated using TRI reagent as directed by the manufacturer (Molecular Research Center, Inc., Cincinnati, OH, USA). Total RNA (10 mg) from the indicated sources was electrophoresed through a 1% agarose formaldehyde gel and transferred to nylon membranes (Micron Separation Inc., Westborough, MA, USA). Probes were labeled by random priming in the presence of 32 P-dCTP as described by the manufacturer (Stratagene, San Diego, CA, USA). The following cDNA probes were used: the full-length rat NaI symporter cDNA (a gift from Dr Nancy Carrasco, Albert Einstein College of Medicine), full-length Pax-8 cDNA (purchased from ATCC), full-length rat cyclophilin cDNA, and a 2.9 kb fragment of the 5 0 end of the mouse thyroglobulin cDNA (a gift from Paul Kim, University of Cincinnati).
